接受每周和每月双磷酸盐治疗的绝经后骨质疏松症患者的健康相关生活质量。

Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates.

机构信息

Department of Endocrinology, University Hospital Zagreb, Zagreb, Croatia.

出版信息

Endocr Res. 2010;35(4):165-73. doi: 10.3109/07435800.2010.505218. Epub 2010 Sep 24.

DOI:10.3109/07435800.2010.505218

PMID:20868288

Abstract

OBJECTIVE

The present study was designed to assess the effect of monthly ibandronate on health-related quality of life (HR-QoL) in patients with postmenopausal osteoporosis previously treated with weekly bisphosphonates.

METHODS

HR-QoL was assessed by Euroqol (EQ-5D) and Osteoporosis Targeted Quality of Life (OPTQoL) questionnaires.

RESULTS

The EQ-5D questionnaire showed significant improvement associated with ibandronate treatment, occurring in mobility (p < 0.01), usual activity (p < 0.01), pain/discomfort (p < 0.05), and anxiety/depression (p < 0.05). In addition, ibandronate treatment considerably improved patients' perceived health on a visual analog scale (p < 0.001). For the OPTQoL questionnaire, patients reported less physical difficulty (p < 0.001), fewer adaptations in their lives (p < 0.001), and less fear (p < 0.001) with ibandronate than with weekly bisphosphonates.

CONCLUSION

The study demonstrated that patients who were transferred from weekly bisphosphonates to a monthly ibandronate experienced improved HR-QoL.

摘要

目的

本研究旨在评估每月伊班膦酸盐对先前接受每周双膦酸盐治疗的绝经后骨质疏松症患者健康相关生活质量（HR-QoL）的影响。

方法

使用欧洲五维健康量表（EQ-5D）和骨质疏松症目标生活质量（OPTQoL）问卷评估 HR-QoL。

结果

EQ-5D 问卷显示伊班膦酸盐治疗与移动能力（p<0.01）、日常活动（p<0.01）、疼痛/不适（p<0.05）和焦虑/抑郁（p<0.05）方面的显著改善相关。此外，伊班膦酸盐治疗显著改善了患者在视觉模拟量表上的自我感知健康（p<0.001）。对于 OPTQoL 问卷，患者报告伊班膦酸盐治疗较每周双膦酸盐治疗时身体困难更少（p<0.001）、生活适应更少（p<0.001）、恐惧更少（p<0.001）。